Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 14/20 | 0.83 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.66 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.66 |
| ▸ | RORC | P51449 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RXRA | P19793 | 1/20 | 0.53 |
| ▸ | RORA | P35398 | 1/20 | 0.53 |
| ▸ | SREBF1 | P36956 | 1/20 | 0.53 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.53 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.53 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.53 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.53 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.53 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.53 |
| ▸ | RORB | Q92753 | 1/20 | 0.53 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.53 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5564305 | 0.91 | HSD11B1 (1.00) | HSD11B1NR1I2NR1H2RORCALDH1A1 | |
| SCHEMBL14613669 | 0.91 | HSD11B1 (0.68) | HSD11B1NR1I2NR1H2RORCALDH1A1 | |
| SCHEMBL5564300 | 0.82 | HSD11B1 (0.76) | HSD11B1NR1I2NR1H2RORC | |
| SCHEMBL5564561 | 0.81 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL5564290 | 0.81 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL5564297 | 0.81 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL14613670 | 0.81 | HSD11B1 (0.82) | HSD11B1NR1I2NR1H2RORCALDH1A1 | |
| SCHEMBL4611779 | 0.80 | HSD11B1 (0.80) | HSD11B1NR1I2NR1H2RORCRORA | |
| SCHEMBL13651537 | 0.80 | NR1I2 (1.00) | HSD11B1NR1I2NR1H2RORCALDH1A1 | |
| SCHEMBL5564146 | 0.79 | HSD11B1 (0.83) | HSD11B1NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076376-B2 | Aniline sulfonamide derivatives and their uses | AMGEN INC. | 2011-12-13 | — | — | US | claimed |
| US-20070021502-A1 | Aniline sulfonamide derivatives and their uses | AMGEN INC. | 2007-01-25 | — | — | US | claimed |
| US-8076376-B2 | Aniline sulfonamide derivatives and their uses | AMGEN INC. | 2011-12-13 | — | — | US | disclosed |
| US-8076376-B2 | Aniline sulfonamide derivatives and their uses | AMGEN INC. | 2011-12-13 | — | — | US | disclosed |
| US-8076376-B2 | Aniline sulfonamide derivatives and their uses | AMGEN INC. | 2011-12-13 | — | — | US | disclosed |
| WO-2007013929-A1 | ANILINE SULFONAMIDE DERIVATIVES AND THEIR USES | AMGEN INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20070021502-A1 | Aniline sulfonamide derivatives and their uses | AMGEN INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021502-A1 | Aniline sulfonamide derivatives and their uses | AMGEN INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021502-A1 | Aniline sulfonamide derivatives and their uses | AMGEN INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021502-A1 | Aniline sulfonamide derivatives and their uses | ARSA, SULT2A1, SULT1A1 | HSD11B1 680/4885NR1I2 63/4885NR1H2 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.